Glowing cancer cells: a new way to see tumors during surgery?

NCT ID NCT07741643

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial tests whether two imaging agents, Panitumumab-IRDye800 and [18F]NOTA-ABY-030, are safe and useful for helping surgeons identify head and neck tumors and cancer-containing lymph nodes during surgery. Adults with head and neck squamous cell carcinoma who are scheduled for tumor removal and neck dissection will receive both agents, and the images will be compared with final pathology results. The goal is to see if this dual-modality approach can improve surgical precision.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Two imaging agents: Panitumumab-IRDye800 (Pan800) and [18F]NOTA-ABY-030
What this could lead to
If successful, this approach could help surgeons remove more cancer tissue during head and neck surgery, potentially improving outcomes and reducing the need for additional treatments.
What could go wrong
This is an early-phase trial with a small number of participants, so the imaging agents may not work as hoped or could cause side effects. The results will need confirmation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.